Autolus Therapeutics plc
AUTL
NASDAQ·Healthcare·Biotechnology·Mkt cap $596.2M
$2.24
▼ -2.18%
P/E
-2.11
Mkt Cap
$596.2M
52-Wk Range
$1.18–$2.58
52-Week Range
$1.18 - $2.58
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 56.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary programmed T cell technology platform enabling multiple cancer indications
- Clinical-stage pipeline with multiple shots on goal across hematologic and solid tumors
- Expertise in next-generation CAR-T cell engineering and manufacturing
- Strategic focus on underserved patient populations with limited treatment options
Bear Case
1 risk
- High volatility (beta 2.0). Larger-than-normal price swings expected.
Growth
Moderate growth ahead
Advancement of AUTO1 through Phase 1b/2 trials with potential breakthrough therapy designation
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+53.4% over 3m
Quality
Thin
Emerging growth company (193% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying AUTL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 11, 2026
Reported EPS of -$0.15 vs -$0.21 consensus (+28.6% surprise). Revenue of $45.7M vs $38.6M expected (+18.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+28.6%
Revenue trend · last 8Q
—
—
-11%
—
—
—
+192%
+118%
Q2 24
Q3 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$9.0M
$20.9M
$21.2M
$24.3M
$26.2M
$45.7M
Margins · last 8Q
Gross
55.2%
Operating
-96.0%
Profit
-85.6%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · May 14, 2026
vs Industry
How AUTL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related